A transformative partnership between Lunit and Labcorp promises to accelerate digital pathology innovations through artificial intelligence. By combining Lunit’s expertise in AI-driven cancer diagnostics with Labcorp’s extensive laboratory services, the collaboration aims to support new breakthroughs in oncology research and clinical care.

Ignite Proteomics has completed the acquisition of PLA code 0249U for its advanced breast cancer assay, integrating laboratory capabilities and intellectual property. This milestone enhances the test’s recognition in billing systems, paving the way for wider adoption in precision oncology.